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Dyskeratosis congenita (DC) was originally deﬁned as a rare inherited bone marrow failure (BMF)
syndrome associated with distinct mucocutaneous features. Today DC is deﬁned by its pathogenetic
mechanism and mutations in components of the telomere maintenance machinery resulting in
excessively short telomeres in highly proliferating tissues. With this new deﬁnition the disease spec-
trum has broadened and ranges from intrauterine growth retardation, cerebellar hypoplasia, and
death in early childhood to asymptomatic mutation carriers whose descendants are predisposed
to malignancy, BMF, or pulmonary disease. The degree of telomere dysfunction is the major deter-
minant of disease onset and manifestations.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction moved into the limelight of biomedical research. The insightsDyskeratosis congenita (DC) is a rare inherited bone marrow
failure (BMF) disorder that has garnered much attention in the last
decade due to its unique pathogenesis. DC is caused by defects in
telomere maintenance. Telomeres are complex DNA–protein struc-
tures that protect the chromosome ends from degradation and
inappropriate recombination and thus are of critical importance
to the cell and the living organism. When the Nobel Prize in Med-
icine was awarded to Elizabeth H. Blackburn, Carol W. Greider, and
Jack W. Szostak in 2009 for the discovery of how chromosomes are
protected by telomeres and the enzyme telomerase, the orphan
disease DC, once an obscure curiosity in pediatric hematology,chemical Societies. Published by E
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iladelphia, PA 19104, USA.gained by studying telomere biology have dramatically changed
how clinicians diagnose and assess patients and their families with
DC. In turn, the study of patients and families with DC has allowed
investigators to delineate the consequences of dysfunctional telo-
mere maintenance in humans [1].
2. Telomeres, telomerase, and human disease
Several excellent reviews have recently summarized our cur-
rent knowledge of the structure and function of telomeres and tel-
omerase [2,3].Telomeres are complex DNA–protein structures at
the ends of chromosomes (see Fig. 1A [4,5]). In most eukaryotes,
including humans, telomeric DNA is composed of guanine-rich
DNA repeat sequences [6]. Telomeres shorten with each cell divi-
sion [7]. When telomeres become critically short a DNA damage re-
sponse is activated causing cell cycle arrest and senescence or cell
death [8]. In quiescent eukaryotic cells the single-stranded 30 over-
hang folds back on the double-stranded telomere forming the t-
loop structure, which serves to protect the chromosome terminus.
Shelterin, a complex of six proteins [telomeric repeat binding fac-
tor 1 and 2 (TRF1, TRF2), TRF1-interacting nuclear factor (TIN2),
protection of telomeres 1 (POT1), TPP1, and RAP1], binds to telo-
meric DNA, protects the telomere structure, facilitates telomeric
DNA replication, and is required for the recruitment of telomerase
to the telomere end (Fig. 1) [9].lsevier B.V. All rights reserved.
Fig. 1. Diagram of the telomere ends and of telomerase and the components mutated in patients with DC. The six proteins of the shelterin complex (TRF1, TRF2, RAP1, TIN2,
TPP1, and POT1) protect the telomere from being recognized as a double strand break and regulate the access of telomerase. Telomerase is a ribonucleoprotein consisting of
the catalytic subunit (TERT), its RNA component TERC, and the four H/ACA RNA associated proteins dyskerin, NHP2, NOP10 and GAR1. The six genes known to be mutated in
patients with DC are highlighted in color. No mutations have been indentiﬁed in GAR1, or the other components of the shelterin complex.
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mechanism that counteracts the process of continuous telomere
shortening [10,11]. The telomerase enzyme is a ribonucleoprotein
complex consisting of the catalytic subunit TERT, its RNA compo-
nent TERC, and the four H/ACA RNA associated proteins dyskerin,
NHP2, NOP10 and GAR1 (see Fig. 1) [12,13]. Telomerase synthe-
sizes telomeric repeat sequences onto the telomeres. Telomerase
is also thought to have extra-telomeric functions important in
stem cell proliferation [14]. In humans after birth telomerase
expression is conﬁned to germ cells, stem cells and their immedi-
ate progeny, activated T cells, and monocytes: all other somatic
cells lack telomerase activity or express telomerase only at very
low levels. Overexpression immortalizes primary human cells from
many tissues [15] and telomerase activation plays an important
role in tumor progression and tumor maintenance (reviewed in
Shay et al. [16]). Notably, most cancer cells express telomerase
activity [8,16]. Despite telomerase expression in stem cells, human
telomeres shorten with age [17,18]. In peripheral white blood cells
rapid telomere shortening occurs within the ﬁrst year of life, fol-
lowed by a more gradual decline over time [19]. Although there
is considerable variation among individuals of the same age, the
relative telomere length is at least in part inherited [20]. Telomere
shortening has been implicated in the mechanism of aging, and
more recently it has been shown to increase the risk of heart dis-
ease and of the development of lung cancer (for review see Harley
[21]).
3. Dyskeratosis congenita
DC was ﬁrst described over 100 years ago and was deﬁned by
the association of three clinical features: dystrophic nails, oral leu-
koplakia (white spots on the tongue and oral mucosa), and abnor-
mal skin pigmentation [22]. While each of these hallmarks may be
seen in other clinical conditions, the presence of all three is patho-
gnomonic of DC. The association of DC with BMF, malignancy, and
pulmonary ﬁbrosis (PF) was recognized later. Historically, the diag-
nosis of DC in a patient with BMF or PF required the presence of at
least one of the three classic mucocutaneous features (for review
see [1]). Other somatic abnormalities have been described in somepatients with DC including epiphora (excessive tears due to the
obstruction of the tear ducts), early graying of the hair, premature
tooth loss, enteropathy with malabsorption, immune deﬁciency,
esophageal stricture, cardiomyopathy, liver cirrhosis, osteoporosis
and avascular necrosis of the bone, urinary tract abnormalities, tes-
ticular atrophy, eye abnormalities, mental retardation, intracranial
calciﬁcations and cerebellar hypoplasia with ataxia [1,23]. Many of
these symptoms are not present at birth but may develop in child-
hood, adolescence, or later in life. Most importantly, patients with
DC have a predisposition for the development of a variety of malig-
nancies, in particular myelodysplastic syndrome (MDS) and sec-
ondary acute myeloid leukemia (AML), head/neck cancer, and
esophageal cancer [24,25]. Malignancies tend to occur earlier in life
compared to the same malignancies in non-DC individuals and are
often the cause of death in patients in the third, fourth and ﬁfth
decade of life. Individuals with DC may develop independent tu-
mors at more than one site [25,26].
4. DC gene mutations and the association with telomere
maintenance
The understanding that DC is caused by defects in telomere
maintenance came with the positional cloning of the gene respon-
sible for the X-linked form of the disease, DKC1, encoding the pro-
tein dyskerin [27], and the subsequent demonstration that
dyskerin is an essential component of the telomerase complex nec-
essary for the stabilization of telomerase RNA [28,29]. The associ-
ation of DC with defective telomere maintenance was conﬁrmed
by the ﬁnding that the dominant form of the disease could be
caused by mutations in other components of telomerase, the telo-
merase RNA [30] TERC and reverse-transcriptase TERT [31]. In some
families in which DC is inherited in a recessive manner mutations
in NOP10 [32] and NHP2 [33] have been shown to be responsible
for the disease. These two proteins associate with dyskerin and
all three proteins are associated with both the telomerase complex
and with H/ACA snoRNPs, nucleolar complexes that catalyze site-
speciﬁc pseudouridylation of nascent ribosomal RNA (see Fig. 1).
Whether ribosomal RNA processing is affected in X-linked or reces-
sive forms of DC and contributes to the pathology is controversial,
Fig. 2. Telomere length distribution in normal controls and patients with BMF due
to DC. The colored lines represent the 1st, 5th, 25th, 50th, 75th, 95th and 99th
percentiles of telomere length determined in peripheral blood mononuclear cells in
250 normal controls between the ages of 1 and 94 years old. In red are the telomere
lengths in peripheral blood mononuclear cells isolated from patients with BMF and
DC in whom a mutation in a DC associated gene was conﬁrmed by genetic testing.
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relate to defective telomere maintenance [34,35]. The sixth DC
gene to be identiﬁed, TINF2, was found in about 10% of clinically
diagnosed DC cases, including many with an early disease onset
and a severe clinical presentation [36]. This gene encodes a protein,
TIN2, that is not in the telomerase complex but is a component of
the protein complex, shelterin, which binds to telomere DNA re-
peats, protecting them from degradation and from DNA repair en-
zymes [9]. How TIN2 mutations cause DC is not yet fully
understood. While the mechanism may involve deprotection of
the telomere ends, we favor the hypothesis that mutations in
TIN2 impair the access of telomerase to the telomere end. TERC
RNA levels and presumably the enzymatic activity of telomerase
are not altered in patients with TINF2mutations [37]. Furthermore,
impaired activity of the telomerase at the telomere end also nicely
explains the phenotypic similarity of patients with the mutations
in the telomerase complex (DKC1, TERC, TERT, NOP10, NHP2) and
patients with mutations in TIN2 residing at the telomere.
In about 50% of patients with the classic features of DC the path-
ogenic mutations have not yet been identiﬁed, suggesting that
additional gene products are involved in the same pathway of telo-
mere maintenance. Notably, no mutations have been identiﬁed so
far in the genes encoding the other ﬁve shelterin-associated pro-
teins (TRF1, TRF2, RAP1, POT1, and TPP1).5. Variable disease penetrance and expressivity
With the knowledge of the genes mutated in DC, genetic testing
became available for family members and for individuals present-
ing similar symptoms but lacking the classic diagnostic features.
Examination of kindreds revealed that TERC or TERT gene muta-
tions that caused DC with the classic mucocutaneous features in
some family members were silent in others (variable penetrance).
In some family members these mutations caused only isolated
clinical features, such as BMF [31], PF [38,39], liver cirrhosis [40],
osteoporosis [41] or MDS [42] (variable expressivity).
Whether patients without the typical mucocutaneous features
or silent mutations carriers should be labeled with DC is controver-
sial. Alternative names have been proposed such as ‘‘syndromes of
telomere shortening” or telomeropathies [43,44]. However, there
are other disorders that are associated with telomere dysfunction
and telomere shortening such as Werner’s syndrome – a prema-
ture aging syndrome caused by mutations in WRN, an ATP-depen-
dent helicase [45], or the Seckel syndrome, a recessive syndrome of
growth retardation and microcephaly due to mutations in ATR
[46–48]. Although these disorders also affect the telomeres and
are associated with telomere shortening in certain cells or tissues,
they are clearly clinically as well as pathogenetically distinct from
DC. Historically it has proven difﬁcult and confusing to change the
name of a disease; thus ‘‘atypical” and ‘‘silent” DC or ‘‘asymptom-
atic mutation carrier” might be better terms for classifying individ-
uals with disease but without the classic mucocutaneous features
or mutation carriers with no clinical detectable disease. The ﬁnding
that in some family members DC may present only with one of the
clinical features associated with DC led to the genetic screening of
patient populations whose primary and only presentation was that
of BMF, PF, or liver cirrhosis and indeed a small (2–10%) but dis-
tinct population in each was found to have disease due to a muta-
tion in a DC associated gene [38–40,49,50]. Although it is often
written that mutations in DC associated genes may cause different
diseases such as BMF, PF, or liver cirrhosis, these conditions have to
be understood as different clinical presentations of one and the
same disease (i.e., DC), and that different clinical presentations
may be found within an individual family carrying the identical
gene mutation. Frequently laboratory signs of additional organdysfunction may be present even in the absence of a clinical dis-
ease phenotype (e.g., even when peripheral blood cell counts are
normal, the bone marrow may be hypocellular and lack the ability
to reconstitute hematopoiesis when used for hematopoietic stem
cell transplantation), or symptoms may develop later in life (e.g.,
the development of PF or liver cirrhosis in patients with DC after
successful hematopoietic stem cell transplantation). In some fam-
ilies disease may only occur under certain circumstances (e.g., BMF
may only occur after a severe infection or after chemo- or radiation
therapy for cancer, or PF may arise only in the setting of tobacco
smoking).
6. Inheritance of DC
In the pre-molecular diagnostic era patients with DC were clas-
siﬁed according to the inheritance pattern of disease as X-linked,
autosomal dominant, or autosomal recessive DC, assuming that
distinct genetic defects would account for the different inheritance
patterns (see also Fig. 3). However, the identiﬁcation of genes mu-
tated in patients with DC and the availability of clinical genetic
testing have shown that the inheritance of disease in patients with
DC may be more complex [41]. Mutations in DC associated genes
may occur sporadically due to de novo gene mutations. In fact
the alanine to valine mutation at amino acid position 353
(A353V) in dyskerin accounting for about 40% of the DKC1 muta-
tions [51] frequently occurs as a de novo mutation and so do the
majority of cases of the R282H and R282C mutations in TINF2. In
contrast, mutations in the TERT and TERC genes are usually inher-
ited, with the exception of G178A and C180T mutations in TERC re-
ported to be present only in the patient but not in either parent
[52]. Mutations in the X-linked DKC1 gene almost always cause
disease in males, even in the ﬁrst generation the mutation occurs.
In contrast, female mutation carriers rarely show disease manifes-
tations because most tissues only express the normal DKC1 allele
due to biased X-chromosome inactivation. Interestingly the
Y139H, V126M and X154Arg NHP2 mutations [33] and the R34W
NOP10 mutation [32] cause disease when homozygous or (in the
case of NHP2 V126M and X154R) compound heterozygous. The
most likely explanation is that these are hypomorphic mutations,
which do not, when present in the heterozygous state, sufﬁciently
impair telomerase activity to cause notable disease. Nevertheless
telomeres in the heterozygous parents were shortened compared
to normal controls, which is consistent with this hypothesis.
Homozygosity or compound heterozygosity have also been
Fig. 3. Model of the pathogenesis of BMF and malignancy in patients with DC. Our hypothesis is that dysfunctional telomeres play a central role in the pathogenesis of BMF
and malignancy in patients with DC. Dysfunctional telomeres cause the activation of the p53 pathway leading to cell cycle arrest, senescence, and cell death in replicating
progenitor cells. Depletion of proliferating progenitor cells recruits new stem cells into cell cycle, thus initiating a vicious cycle that ultimately leads to the depletion of stem
cells and to the clinical picture of AA. Increased oxidative stress in the environment of BMF and defective ribosome biogenesis in the X-linked and some rare autosomal
recessive forms of DC may additionally contribute to the activation of the p53 pathway. Dysfunctional telomeres cause genomic instability that leads to cancer predisposition
in patients with DC.
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mutations [41,53,54] showing recessive inheritance in the affected
family. Interestingly homozygous or compound heterozygous TERT
or TERC gene mutation carriers often have more severe disease
compared to heterozygous mutation carriers and not uncommonly
present with the classical features of DC (see also Fig. 4). However,
in contrast to mice homozygosity or compound heterozygosity for
telomerase null mutations have not been described in humans,
suggesting that these are incompatible with life in humans. Simi-
larly no DKC1 null mutation has been described in patients with
DC. This might be due to the essential role of dyskerin in ribosome
biogenesis, but could also be due to its role in telomere mainte-
nance, as pathogenic DKC1 mutations may greatly diminish but
not completely abolish the accumulation of telomerase RNA, TERC,
in the cell.
7. Anticipation in DC
DC shows a unique and previously unknown form of disease
anticipation. Disease anticipation is an increase in disease severity
in later generations carrying a gene mutation. Most human dis-
eases showing anticipation are neurological conditions caused by
repeated trinucleotide sequences in a gene [55]. These are often
CAG repeats and encode polyglutamine in the mature protein,
though in some cases they are other sequences and can be in
non-protein encoding regions. These repeats can expand by un-
equal crossing over during meiosis and can increase in length as
they are passed from generation to generation. Classic examples
are Huntington’s disease [56] and the fragile X mental retardation
syndrome [57]. Anticipation in DC has a different mechanism – it is
due to telomere shortening and the inheritance of shortened telo-
meres, such that early generations carrying a TERC or TERT muta-
tion may be unaffected, but in later generations telomeresbecome critically short and affect the ability of stem cells to contin-
ually renew tissues with a high cellular turnover. Initially anticipa-
tion was described in telomerase null mice who only develop a
disease phenotype after several rounds of inbreeding, and experi-
ments in mice have elegantly shown that this is due to the inher-
itance of subsequently shorter telomeres with each round of
inbreeding [58,59]. Anticipation has also been documented in cer-
tain families with the autosomal dominant form of DC [60–62].
These families show increased severity of disease and earlier age
of onset in later generations. Anticipation in the X-linked form is
more difﬁcult to observe, most likely because in females, due to
X-inactivation in early embryogenesis and the subsequent selec-
tive growth advantage of cells expressing the normal DKC1 allele,
the mutated DKC1 gene is usually on the inactive X-chromosome
and thus is not expressed. Thus, when the DKC1 gene mutation is
alternately passed through females (male to male inheritance does
not occur for X-linked DC) telomere length is usually restored at
least to some degree. Whether disease anticipation may be ob-
served between grandfather and grandson is hard to determine be-
cause of the rarity of the disease and the fact that X-linked DC is
often associated with decreased male fertility.
8. Mutations in DC associated genes
Sequence alterations in DC associated genes are summarized
in the Telomerase Database (http://telomerase.asu.edu/diseases.
html) along with references to the original work. In X-linked DC,
with the exception of a small terminal deletion removing the last
22 amino acids of dyskerin and an in-frame deletion of a single
amino acid (L37) mutations in dyskerin are mainly point mutations
causing a single amino acid change, suggesting that these are all
hypomorphic mutations with some residual dyskerin function
(see also above). The promoter and splice site mutations described
Fig. 4. Age-related variable disease expression of mutations in DC associated genes. The clinical phenotype of mutations in DC-related genes varies with the age of onset.
Mutations that most severely compromise telomere maintenance manifest early in life leading to the more severe forms of DC including the HHS (Hoyeraal Hreidarrson
syndrome) or RS (Revesz syndrome) They may be caused by mutations in the DKC1 and TINF2 gene. Classic DC is most frequently caused by DCK1 gene mutations or
homozygous or compound heterozygous mutations in the TERC or TERT genes. Heterozygous mutations in TERC or TERT genes may be associated with BMF, whereas mucco-
cutaneous features may be mild or missing (aplastic anemia, AA). Pulmonary ﬁbrosis (PF), liver ﬁbrosis (LF) and osteoporosis (OP) are DC manifestations that clinically
become obvious later in life. They may present as the only clinical feature in patients heterozygous for TERT or TERC gene mutations. Malignancy (cancer and MDS/AML) is
most frequently seen in patients with mild-moderate disease severity and occurs most frequently in the third, fourth and ﬁfth decade. In patients with TERT or TERC gene
mutations, MDS or MDS/AML might be the initial presentation at diagnosis. The severity and the duration of dysfunctional telomere maintenance are important factors that
determine the disease pathology. M = mutant.
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solving of the crystal structure of dyskerin revealed that patho-
genic DKC1 mutations cluster in the RNA binding domain of dysk-
erin [63–65], which is consistent with the decreased TERC RNA
levels in dyskerin mutant cells. Large and small TERC RNA deletions
have been described to be responsible for the development of auto-
somal dominant DC. Point mutations alter the tertiary structure of
the RNA affecting activity or processivity of the telomerase en-
zyme, or the stability of the RNA. Mutations in TERT spread
throughout the coding sequence and may affect any of its three do-
mains, the N-terminal region, reverse-transcriptase motifs, or the
C-terminal region. The study of 45 individuals with a de novo chro-
mosomal deletion spanning the TERT gene showed that telomere
shortening, although marginally accelerated, was not sufﬁcient to
cause a DC-related disease in the absence of anticipation [66].
Alternatively, it is possible that in patients with a gene deletion
compensatory mechanisms exist that might not operate in patients
who express a mutant protein. Interestingly in patients with DC
due to TINF2 mutations the mutations cluster in exon 6 [36,37].
The mutations spare the TRF1 binding site, with TIN2 mutations
after the binding site giving rise to a more severe phenotype (see
also below).
The majority of mutations in patients with DC are unique or pri-
vate mutation occurring in an individual family with DC. Excep-
tions are the A353V mutation in DKC1 and R282H and R282C
TINF2 that are recurrent mutations. Occasionally DKC1 or TERT
gene mutations have been described independently in more than
one family. Interestingly the recurrent A353V mutation in DKC1
and the R282H and R282C in TINF2 most frequently occur sporad-
ically (see also above) suggesting that these occur within muta-
tional hotspots and indeed these three mutations all arise fromthe relatively frequent CpG to TpG transitions that can occur by
deamination of the cytosine residue [37]. This cannot wholly ex-
plain the high frequencies of these mutations, and it is expected
the role of these frequently mutated residues will hold important
clues about the pathogenetic mechanism.
The fact that many of the gene alterations are only described
once in a patient or family makes it difﬁcult to determine whether
the identiﬁed sequence alteration is indeed responsible for disease
(pathogenic). This is more difﬁcult when the same gene alteration
has also been identiﬁed in unaffected family members or even in
unrelated individuals, as can happen because of the variable pene-
trance of TERC and TERT mutations. Functional in vitro assays of
telomerase activity or quantitative measurements of the level of
telomerase RNA may support the diagnosis but often lead to vari-
able results depending on the investigator. Moreover in vitro telo-
merase activity may not necessarily reﬂect the telomerase activity
at the telomere end in vivo. Family studies and segregation with
disease or short telomeres may lend support, but cannot on their
own necessarily consolidate or exclude the pathogenicity of a no-
vel identiﬁed gene alteration.
Several polymorphism have been described in DKC1, TERC, TERT
and TINF2 genes, some of which have been shown to affect the
expression levels of the respective cDNA or decrease the in vitro
telomerase activity (functional polymorphism). However, to what
extent these functional polymorphisms contribute or predispose
to the development of disease is unclear and remains to be deter-
mined. In the context of genetic counseling or clinical decision-
making such genetic variations should be carefully interpreted to
avoid unnecessary anxiety in a patient who may remain healthy
or to exclude a transplant from a sibling donor who otherwise
has no clinical or laboratory signs of disease.
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That all of the known DC associated genes are involved in telo-
mere maintenance suggests that telomere dysfunction is the com-
mon denominator in this disease and that dysfunctional telomeres
play an important role in pathogenesis. Indeed, patients with DC
and BMF have very short telomeres (see Fig. 2) [50,67,68]. The
measurement of telomere length in peripheral blood cells has
therefore become increasingly used as a screening test to identify
patients with DC. Amongst patients with BMF the ﬁnding of very
short telomeres (1st percentile in peripheral mononuclear cells
or lymphocytes) has been shown to be highly sensitive, although
not necessarily speciﬁc, for the diagnosis of DC. In other words,
normal telomere length excludes DC as a cause of BMF, whereas
the ﬁnding of short telomeres is not necessarily diagnostic of DC
[50]. Other BMF syndromes have also been shown to be associated
with short telomeres but the telomeres are usually not as short as
in patients with BMF due to DC, particularly in children. Leukocyte
telomere length in normal healthy individuals decreases with age,
as seen when age is plotted against telomere length for a large
number of individuals (see Fig. 2). Interestingly, this is not seen
when the same data from patients with DC and BMF is plotted;
rather, patients with DC have very short telomeres whose length
does not vary with age. This suggests that at the time of clinically
apparent BMF peripheral blood leukocytes have reached their min-
imal length in patients with DC [50]. Consequently, in children
with BMF the difference in telomere lengths between patients with
and without DC is dramatic, whereas in older patients with BMF
the telomere lengths of patients with and without DC overlap.
Thus, telomere length measurements are a more sensitive diagnos-
tic tool for detecting DC in the setting of BMF in children than in
older adults [50]. Mutation carriers (mainly TERC and TERT) who
do not have clinical manifestations of BMF often have telomere
lengths that are shorter than average, but due to the overlapping
distribution of telomere lengths in the population this is not a sen-
sitive test with which to identify a mutation carrier from a normal
control. This is particularly true in families with DC, because short
telomeres, but not the pathogenic mutation, may have been inher-
ited from the affected parent. The clinical signiﬁcance of short telo-
meres by inheritance in the absence of a DC gene mutation is
currently under study. The investigation of large families has
shown that two generations without a DC gene mutation are
needed to restore normal telomere length in these families [62].
Similarly, these family studies have shown that in the absence of
BMF, normal telomere length does not exclude a silent mutation
carrier. Thus, in the absence of BMF, genetic testing is essential
for the diagnosis of DC or for the identiﬁcation of a silent mutation
carrier [50].
10. Model for the pathogenesis of BMF and malignancy in
patients with DC
Telomere ends are protected from degradation and inappropri-
ate recombination mainly by two mechanisms: (1) the formation
of a loop like structure (t-loop), and (2) the shelterin complex
(see Fig. 1). Dysfunctional telomeres were initially thought to be
telomeres that have become too short to adopt the t-loop struc-
ture. Recently it has been shown that telomeres may also become
dysfunctional due to a capping defect caused by abnormalities in
the shelterin complex that may be independent of telomere length
[69,70]. Our working model is that hematopoietic progenitor cells
that have dysfunctional telomere ends will trigger a DNA damage
response that will lead them to irreversibly cease to divide and un-
dergo senescence or possibly die. Dysfunctional telomeres aremost likely to occur ﬁrst in rapidly dividing hematopoietic progen-
itor cells. The loss of dividing progenitor cells starts a vicious cycle
by increasing the number of stem cells recruited into cell cycle un-
til the telomeres of hematopoietic stem cells are eroded. The loss of
dividing hematopoietic progenitor cells, and ﬁnally stem cells,
leads to irreversible BMF. Dysfunctional telomeres activate the
p53 pathway and increase genomic instability leading eventually
to a cell crisis, cell cycle arrest, senescence or cell death. Rare cells
that escape cell senescence or cell death and have acquired a
mechanism to maintain telomere integrity emerge from the crisis
as potentially malignant cells. A schematic diagram of our model
of BMF and tumorigenesis is shown in Fig. 3.
In normal individuals the telomeres are maintained by three
mechanisms: (1) hematopoietic stem cells have low level telome-
rase activity that compensates, at least in part, for the gradual loss
of telomere length caused by cell division, maintains telomere
integrity, and protects from DNA damage; (2) under normal cir-
cumstances most stem cells are quiescent; (3) telomeres in normal
individuals are long enough that even as telomeres shorten with
age they rarely reach the critical length that leads to irreversible
cell cycle arrest. In patients with DC four mechanisms may directly,
or indirectly through increased p53 activation and increased stem
cell turnover (replicative stress) contribute to dysfunctional telo-
meres. These include: (1) reduced telomerase activity at the telo-
mere end; (2) the inheritance of short telomeres; (3) increased
DNA damage response at the end of telomeres; (4) oxidative
DNA damage in the environment of BMF; and (5) for the X-linked
and rare autosomal recessive forms of DC impaired ribosome bio-
genesis (see Fig. 3).
11. Age-related variable expression of mutations in telomere
maintenance genes
Abnormalities caused by mutations in telomere maintenance
genes vary with the age of onset of disease (see also Fig. 4). Onset
at a young age is consistent with severe disease and often causes
death in early childhood. The clinical picture is characterized by
the presence of immunodeﬁciency, BMF, microcephaly, cerebellar
hypoplasia, and growth retardation. Crohn-like gut abnormalities
and malabsorption often additionally complicate early onset of dis-
ease. This set of abnormalities, originally described as Hoyeraal
Hreidarrson syndrome (HSS), is now recognized to be an early on-
set and severe form of DC (associated with mutations in DKC1,
TINF2 and other unknown genes). Sometimes BMF is found with
bilateral retinopathy and some other DC features in infants in Re-
vesz syndrome, caused by mutations in TINF2.
In older children and teenagers, classic DC with the triad of
mucocutaneous features and BMF is the most frequent DC presen-
tation and is caused by mutations in DKC1 or TINF2, with TINF2
patients presenting on average earlier than DKC1 patients.
Occasionally the classic presentation of DC is caused by homozy-
gous or compound heterozygous mutations in TERC or TERT
[41,53,54].
Later in life TERC and TERT gene mutations are often found in
patients presenting with aplastic anemia in the absence of muco-
cutaneous features. Older patients may also present with familial
or apparently idiopathic PF or with liver disease. Mutations in TERC
or TERT are usually responsible for these cases.
Cancer in patients with DC usually occurs in the third decade
with head and neck cancer and MDS being the most common
malignancies and in the early ﬁfties with MDS/AML being more
frequent. Mainly patients with moderate or mild forms of DC or
those who have received hematopoietic stem cell transplant devel-
op malignancies, whereas patients with severe forms of DC usually
die from the disease before the development of malignancy.
M. Bessler et al. / FEBS Letters 584 (2010) 3831–3838 3837The difference in age dependent disease expression is intriguing
and unique. It suggests that depending on the degree of telomere
maintenance dysfunction, different tissues are predominantly af-
fected. This might be due to the fact that different highly prolifer-
ative tissues ‘‘run out” of telomeres at different time points. For
example cerebellar neuronal cells might run out of telomeres only
in very severe cases of telomere dysfunction, whereas hematopoi-
etic progenitor cells are much more sensitive and might be affected
by only minimal changes. An alternative explanation is that it is
not telomere dysfunction but the pattern and levels of p53 expres-
sion and the sensitivity of cells to increased levels of p53 that dic-
tates the clinical picture. For example high levels of p53 expression
in embryonic development causes cell death in neuronal cells and
retina, moderate levels of p53 expression causes replicative senes-
cence in hematopoietic progenitor cells, whereas low but chronic
level of p53 expression causes senescence in pneumocytes and
ﬁbrosis in lung and liver tissue [71].
12. Summary
Insights gained into telomere biology have transformed our
understanding of DC and the approach to patients and families
with this disorder. In turn studying the clinical manifestations of
DC have shed light on the fundamental importance of maintaining
the telomere ends. A better understanding of how telomeres are
maintained may eventually yield new treatment options for pa-
tients and families with DC.
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